All Curated Mutation Sites in HPV

The Virus Mutation(VM) module provides researchers the annotations of reported pathogenic mutations in HPV related to human diseases. The curated VM information includes mutation site, mutation level, virus gene/protein/region, virus-associated disease, genotype/subtype, literature evidence, etc.

Browse Data by Virus Gene/Protein/Region, Disease OR Description

*Please select one option you are interested in, the page will be automatically redirected.

Virus Gene/Protein

Disease

Description

Click the button below to quickly view the viral genes/regions/protein for mutation

Show All

E1^E4

Keyword: Uterine Cervical Neoplasms-32448303

ID	PMID	Mutation	Gene/Protein/Region	Encoding Gene/Protein	Disease	Description	Detail
1	32448303	T104C	LCR		Uterine Cervical Neoplasms	G R S L	View
2	32448303	A345T	L1	L1	Uterine Cervical Neoplasms	G R S L	View
3	32448303	A5467G	L1	L1	Uterine Cervical Neoplasms	G R S L	View
4	32448303	A5497G	L1	L1	Uterine Cervical Neoplasms	G R S L	View
5	32448303	A5560C	L1	L1	Uterine Cervical Neoplasms	G R S L	View
6	32448303	A5678C	L1	L1	Uterine Cervical Neoplasms	G R S L	View
7	32448303	A6059G	L1	L1	Uterine Cervical Neoplasms	G R S L	View
8	32448303	A6155G	L1	L1	Uterine Cervical Neoplasms	G R S L	View
9	32448303	A6401G	L1	L1	Uterine Cervical Neoplasms	G R S L	View
10	32448303	A6430C	L1	L1	Uterine Cervical Neoplasms	G R S L	View
11	32448303	A6441C	L1	L1	Uterine Cervical Neoplasms	G R S L	View
12	32448303	A6823G	L1	L1	Uterine Cervical Neoplasms	G R S L	View
13	32448303	A6970G	L1	L1	Uterine Cervical Neoplasms	G R S L	View
14	32448303	C5478T	L1	L1	Uterine Cervical Neoplasms	G R S L	View
15	32448303	C5701G	L1	L1	Uterine Cervical Neoplasms	G R S L	View
16	32448303	C5875A	L1	L1	Uterine Cervical Neoplasms	G R S L	View
17	32448303	C5920T	L1	L1	Uterine Cervical Neoplasms	G R S L	View
18	32448303	C6460G	L1	L1	Uterine Cervical Neoplasms	G R S L	View
19	32448303	C6625G	L1	L1	Uterine Cervical Neoplasms	G R S L	View
20	32448303	C6842G	L1	L1	Uterine Cervical Neoplasms	G R S L	View
21	32448303	G5609A	L1	L1	Uterine Cervical Neoplasms	G R S L	View
22	32448303	G6462A	L1	L1	Uterine Cervical Neoplasms	G R S L	View
23	32448303	G6701A	L1	L1	Uterine Cervical Neoplasms	G R S L	View
24	32448303	G7032A	L1	L1	Uterine Cervical Neoplasms	G R S L	View
25	32448303	H13R	L1	L1	Uterine Cervical Neoplasms	G R S L	View
26	32448303	H44P	L1	L1	Uterine Cervical Neoplasms	G R S L	View
27	32448303	N465S	L1	L1	Uterine Cervical Neoplasms	G R S L	View
28	32448303	T5619A	L1	L1	Uterine Cervical Neoplasms	G R S L	View
29	32448303	T6131G	L1	L1	Uterine Cervical Neoplasms	G R S L	View
30	32448303	T6146G	L1	L1	Uterine Cervical Neoplasms	G R S L	View
31	32448303	T6650G	L1	L1	Uterine Cervical Neoplasms	G R S L	View
32	32448303	T6809C	L1	L1	Uterine Cervical Neoplasms	G R S L	View
33	32448303	T6941C	L1	L1	Uterine Cervical Neoplasms	G R S L	View
34	32448303	T6953C	L1	L1	Uterine Cervical Neoplasms	G R S L	View
35	32448303	C751T	E7	E7	Uterine Cervical Neoplasms	G R S L	View
36	32448303	C860T	E7	E7	Uterine Cervical Neoplasms	G R S L	View
37	32448303	A171G	E6	E6	Uterine Cervical Neoplasms	G R S L	View
38	32448303	A482C	E6	E6	Uterine Cervical Neoplasms	G R S L	View
39	32448303	A560G	E6	E6	Uterine Cervical Neoplasms	G R S L	View
40	32448303	C158T	E6	E6	Uterine Cervical Neoplasms	G R S L	View
41	32448303	C287G	E6	E6	Uterine Cervical Neoplasms	G R S L	View
42	32448303	C549A	E6	E6	Uterine Cervical Neoplasms	G R S L	View
43	32448303	C554T	E6	E6	Uterine Cervical Neoplasms	G R S L	View
44	32448303	F71L	E6	E6	Uterine Cervical Neoplasms	G R S L	View
45	32448303	N113K	E6	E6	Uterine Cervical Neoplasms	G R S L	View
46	32448303	T173G	E6	E6	Uterine Cervical Neoplasms	G R S L	View
47	32448303	T317G	E6	E6	Uterine Cervical Neoplasms	G R S L	View
48	32448303	T443G	E6	E6	Uterine Cervical Neoplasms	G R S L	View
49	32448303	T485C	E6	E6	Uterine Cervical Neoplasms	G R S L	View

Contents
Description

The table shows all curated mutation sites of HPV in each literature

Table Description Column Note

D
The study mentioned a certain treatment method, such as drug resistance caused by mutations.

G
The study mentioned the virus genotype/subtype information.

R
The study mentioned the reference sequence used for comparison, or the original strain of the virus used for site-directed mutagenesis.

S
The study provided sequence information or accession numbers.

L
The study provided the geographic region/country of data origin.

C
The study provided clinical baseline information.

I
The study involved information related to immune.

T
The study involved host target genes.